MDHearing NEO XS Review
The short version
The MDHearing NEO XS is a $397 completely-in-canal (CIC) hearing aid, backed by a 60-day trial and a 1-year warranty - notably longer trial terms than MDHearing's own VOLT MAX. The thing worth knowing before anything else: two independent lab-testing outlets rate its controlled sound performance poorly, while Consumer Reports' own usability-focused review found it easy to use with very good daily performance. That's a real split between sources, not a smoothed-over verdict - both sides are laid out below.
What independent testing actually found
Professional assessment: this is a genuine three-way split, and it's worth being precise about what kind of split it is - all three sources here are professional/editorial testing outlets, not a lab-versus-consumer-review comparison. HearAdvisor gives the NEO XS a SoundGrade of C, SoundScore 2.47 out of 5, ranking it #47 of 61 OTC devices tested. Its standout strength is feedback handling - excellent whistling control at 5.0/5 - but speech-in-quiet scored just 1.0/5, and speech-in-noise scored -0.2/5, below zero on HearAdvisor's own scale (hearadvisor.com). HearingTracker separately places it "in the bottom 5% of all products tested" (hearingtracker.com). Consumer Reports, by contrast, tested it and found it "very easy to use with very good performance for daily use" (consumerreports.org) - a meaningfully more positive read than the two lab-test outlets. We're presenting all three plainly rather than picking a side.
Consumer sentiment: distinct from the professional split above, and unresolved. We checked for an independent retailer or consumer-aggregate rating (Amazon, in particular) across three separate research passes and found none we could verify. MDHearing's own on-site review widget shows 3.9 stars from 812 reviews, but that's the brand's own site, not an independent channel, so we're not using it here - same standard this site applies to every model. If a verifiable third-party consumer rating turns up later, we'll add it.
Trial period and warranty
MDHearing backs the NEO XS with a 60-day risk-free trial - notably longer than the 45-day trial confirmed for the sibling VOLT MAX - and a 1-year warranty against defects in materials and workmanship from the date of order receipt (mdhearingaid.com; Consumer Reports).
A few practical specifics: the NEO XS is rechargeable, rated for about 18 hours per charge (2 hours to charge the device, 3 hours to charge the case). It has no IP water/dust rating - three independent outlets (Consumer Reports, HearReviews, HearingTracker) agree it isn't water resistant. It has no telecoil (that's exclusive to MDHearing's separate AIR model, per the brand-wide pattern already confirmed for VOLT MAX) and no Bluetooth or app control - it's fully on-device, controlled by a single multi-use push-button on the faceplate: a short press adjusts volume, a long press cycles through 4 preset programs (Quiet, Social, Noisy, Restaurant). That's a real difference from MDHearing's own NEO XS PRO SKU, which does offer Bluetooth. It's intended for mild-to-moderate hearing loss.
MDHearing's stated policy allows an exchange within the 60-day trial window, which resets the trial clock to a fresh 60 days from the new device's delivery date - you'll need to contact customer service before returning devices, and accessory-only returns aren't honored on their own. Return shipping is stated as free under MDHearing's policy, matching what's already confirmed for the sibling VOLT MAX, though this specific figure comes from a single source rather than being independently re-verified for NEO XS.
One thing we couldn't pin down with confidence: whether the NEO XS can be purchased or replaced as a single hearing aid rather than as a pair. There's a thin lead suggesting it might be, but it's an inference from packaging details rather than a direct statement from MDHearing, so we're not asserting it either way - contact MDHearing directly if that matters to you.
The HSA/FSA math
At $397 for the pair, here's the effective out-of-pocket cost using pre-tax HSA or FSA dollars, by marginal tax bracket:
| Tax bracket | Effective cost after HSA/FSA savings |
|---|---|
| 12% | $349 |
| 22% | $310 |
| 32% | $270 |
This is arithmetic, not tax advice - your actual savings depend on your specific plan and eligible-expense rules. Check with your plan administrator before assuming reimbursement. MDHearing's checkout is understood to be HSA/FSA eligible as a brand-wide policy (already confirmed for the sibling VOLT MAX), though that hasn't been independently re-verified as NEO-XS-specific this run.
Ownership/market context
MDHearing is privately held and Chicago-based (founded 2008 or 2009, depending on the source), with a company-database listing showing at least one outside investor it doesn't name on its free tier. This is a brand-wide fact already established for the sibling VOLT MAX review, not independently re-researched for NEO XS specifically - we're not naming a specific investor since our source doesn't.
What we couldn't confirm
- Consumer-aggregate rating: no independent, verifiable retailer or consumer-aggregate star rating found for this specific model, despite checking across three separate research passes. MDHearing's own on-site widget (3.9/5, 812 reviews) exists but isn't independent, so we're not using it.
- Single-ear purchase/replacement: a thin, inference-based lead exists but isn't solid enough to state as confirmed policy.
- Tinnitus masking: a single independent source (HearingTracker) states the NEO XS doesn't offer tinnitus maskers; not yet cross-checked against a second outlet.
- Return shipping and mid-trial exchange terms: sourced to MDHearing's own stated policy language, matching the brand-wide pattern already confirmed for VOLT MAX, but not independently re-verified as NEO-XS-specific.
- Telecoil and parent-company ownership: both are brand-wide facts transferred from the already-confirmed VOLT MAX entry, not independently re-researched for this specific model.
Disclosure
Drafted with AI assistance from HearingScout's verified product database; reviewed and fact-checked against primary sources before publishing. See our methodology for how we evaluate every device.